| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) treatment dramatically decreased the viability of HT-29 colon cancer cells in a way that was dependent on both time and concentration. Hexahydrocurcumin's IC50 values were 56.95 and 77.05 after 24 and 48 hours of exposure, respectively [1]. Combining 5-fluorouracil (5-FU; 5 μM) with hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) dramatically decreased COX-2 expression. Levels of COX-1 remain constant [1]. COX-2 protein was dramatically reduced by hexahydrocurcumin (0-25 μM; 24-48 hours; HT-29 cells) in combination with 5-fluorouracil (5-FU; 5 μM). The amounts of COX-1 protein are unaltered [1]. In murine macrophages (RAW 264.7), lipopolysaccharide (LPS)-induced rise in prostaglandin E2 (PGE2) is attenuated in a concentration-dependent manner by hexahydrocurcumin (7–14 μM; 24 hours) [2].
|
|---|---|
| ln Vivo |
Rats with colon cancer who received oral hexahydrocurcumin treatment (50 mg/kg; daily; for 16 weeks; male Wistar rats) had a significant decrease in the number of aberrant crypt foci (ACF). Moreover, hexahydrocurcumin dramatically lowered COX-2 protein expression. Rats with normal COX-1 protein levels are not different [3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HT-29 Cell Tested Concentrations: 0 µM, 5 µM, 10 µM, 25 µM Incubation Duration: 24 hrs (hours) or 48 hrs (hours) Experimental Results: Dramatically diminished the viability of HT-29 colon cancer cells. RT-PCR[1] Cell Types: HT-29 Cell Tested Concentrations: 25 µM Incubation Duration: 24 hrs (hours) Experimental Results: Combination with 5-fluorouracil (5-FU; 5 µM) Dramatically diminished COX-2 expression. Western Blot Analysis[1] Cell Types: HT-29 Cell Tested Concentrations: 25 µM Incubation Duration: 24 hrs (hours) Experimental Results: Combined use with 5-fluorouracil (5-FU; 5 µM) Dramatically diminished COX-2 protein. |
| Animal Protocol |
Animal/Disease Models: Male Wistar rats (100-120 g) were injected with dimethylhydrazine (DMH) [3]
Doses: 50 mg/kg Route of Administration: Oral; injection. Daily; continued for 16 weeks Experimental Results: The amount of ACF was Dramatically diminished in rats with colon cancer. COX-2 protein expression was also Dramatically diminished. |
| References |
|
| Additional Infomation |
Hexahydrocurcumin is a diarylheptanoid.
Hexahydrocurcumin has been reported in Zingiber officinale with data available. |
| Molecular Formula |
C21H32O6
|
|---|---|
| Molecular Weight |
380.47518
|
| Exact Mass |
374.172
|
| CAS # |
36062-05-2
|
| PubChem CID |
5318039
|
| Appearance |
White to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
622.6±55.0 °C at 760 mmHg
|
| Melting Point |
80-82℃
|
| Flash Point |
218.4±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
1.49
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
27
|
| Complexity |
442
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~267.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.68 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL | |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
